Specialty Pharmacy: Stakeholders, Strategies and Markets 2007 (Third Edition)

Table of Contents Photo of Book Written By Written For AIS Guarantee Shipping Information Related Publications		Order Now (secure site)  Print edition Print & CD editions (see details below) View Cart
Place an order or get more information at 800-521-4323 Prices Print edition: $312 Print & CD editions: $462 Pages: 290 ISBN: 1-933801-06-9 © 2006 Pub Code: GSPRX3

The specialty pharmacy industry is evolving at an extremely rapid pace to manage the influx of new biotech and injectable drug products that is hitting the marketplace. This field is growing more than 20% per year, and some experts estimate it may be worth $40 billion in 2007. It’s critical that you understand how these new technologies and therapies will be identified, delivered and paid for.

Specialty Pharmacy: Stakeholders, Strategies and Markets is a valuable one-of-a-kind book full of hard data and statistics on the vendors serving the market, the products involved, and the strategies employed by payers for managing and delivering these products to its members.

The 2007 edition provides readers with unique insight and data on major developments in the market, including:

• Consolidation in the specialty pharmacy and PBM industries, including major acquisitions of home infusion companies
• Distribution strategies, benefit strategies, and sales results for significant new products such as Tysabri, Bexxar, Baraclude, Ventavis, Vivaglobin, Abraxane, Revlimid, Nexavar, Kepivance, Orencia, Saizen, Macugen, Myetta, Thyrogen, Pulminiq, Carticel and Increlex
• Competitive impact of new distribution contracts and new drug launches
• PBM strategies and alliances for competing in the specialty pharmacy space
• Health plan formulary strategies for specific disease states such as oncology, pulmonary arterial hypertension, rheumatoid arthritis, respiratory syncytial virus, infertility, Crohn’s disease/colitis/irritable bowel syndrome, hepatitis, opthalmology, etc.
• Impact of new Average Sales Price (ASP) reimbursement methodologies, Medicare’s Competitive Acquisition Program (CAP) for physician-administered therapies and Part D versus Part B reimbursement controversies
  

• Decisions in Building a Specialty Pharmacy Program
• Provider Contracting Issues
• Strategies of Specific Managed Care Organizations

• Medical Benefit vs. Pharmacy Benefit vs. Integrated Benefit Design
• Trends in Therapy Management
• Member Cost-Sharing Strategies
• Formulary Placement and Product Preferencing
• Biosimilar Opportunities
• Drug Safety
• Other Management Issues

• Oncology
• Pulmonary Arterial Hypertension (PAH)
• Rheumatoid Arthritis
• Respiratory Syncytial Virus (RSV)
• Fertility
• Crohn’s Disease/Colitis/Irritable Bowel Syndrome
• Hepatitis
• Ophthalmology

• Class of Trade Issues
• Payer-Centric Business Models
• Mergers & Acquisitions Focus on Capabilities Expansion
• Home Infusion, Specialty Infusion Drive New Business Models
• Group Purchasing Organizations
• Disease Management
• Legal Challenges and Considerations

• Medicare Part B Physician Fee Schedule
• Average Sales Price (ASP)-Based Reimbursement for
• Medicare Part B Drugs and Biologicals
• Competitive Acquisition Program (CAP) for Physician-Administered Drugs
• Part D vs. Part B Reimbursement Controversies

• Manufacturer Distribution Strategies
• New Drug Launches and Payer Reaction
• FDA Approvals and Expanded Indications

• Vendor Comparison Analysis
• Business Volume Indicators
• Comprehensive Directory of Specialty Pharmacy Vendors

Written By

Specialty Pharmacy: Stakeholders, Strategies and Markets is written by the staff of Atlantic Information Services, Inc.

Written For

• Managed care payers
• Disease management companies
• Pharmaceutical retailers
• Physicians
• Pharmaceutical and biotech developers and manufacturers
• Pharmacy benefit managers
• Pharmaceutical distributors
• Home health providers
• Specialty outpatient clinics
  

Advertise With AIS

Privacy

Site Map